GlobeNewswire

Zageno and Thomas Scientific to Launch New, Fast and Easy Way to Choose and Purchase the Right Lab Products for Each Specific Experiment at Pittcon, Booth 2423

Dela

Continuously innovating to serve its customers better, century-old Thomas Scientific-the third largest and fastest-growing scientific-equipment company is leveraging startup Zageno, the largest and fastest-growing online marketplace dedicated to the research scientist. Zageno's new platform enables scientists to choose the best products to advance science using a ranking score based on millions of unbiased scientific publications; helps customers procure their products through better integration into their existing processes.

 

ORLANDO, Fla. USA and BERLIN, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Zageno Inc., an online biotech marketplace, and Thomas Scientific - a brand-centric, broad-line life-science-equipment, instrument, furniture, consumable, chemical, and laboratory safety supplier with nearly one million high-quality products - announced a U.S. commercial agreement, where Zageno will feature Thomas Scientific's full spectrum of offerings on the Zageno platform. Products are organized logically by process steps and methods (e.g. preparation gene editing; amplification separation: antibodies detection) so research scientists can search and order Thomas's portfolio of products easily, enabling more focus on performing their experiments instead of gathering supplies.

 

Commenting on its latest addition to its life science vendor partner list, Zageno Cofounder and Chief Revenue Officer Florian Wegener, M.D., M.B.A., Ph.D., said, "With its breadth of product offerings from world-leading brands, century-long commitment to serving the research community, and tireless focus on getting things right for customers - Thomas Scientific was a natural vendor partner for Zageno. We're proud to share their booth at Pittcon 2018, where we'll be honored to demonstrate how Zageno can make it easy for Thomas Scientific customers to save time and make better purchasing decisions for their specific scientific studies."

"We're thrilled to enter into this partnership with Zageno," said Thomas Scientific President and Chief Executive Officer Charles Simmons. "Zageno opened up a valuable channel for new customers, allowing us to optimize the focus of our field-based sales force. As an added benefit, Zageno has been able to integrate with our order-intake process, to make our operations more efficient, and make things easy and seamless for the customer."

In creating a biotech-specialized online marketplace, Zageno's founders recognized that scientific product comparison is different than comparing commercial products. Scientists need more information than is readily available on product packaging; nomenclature often varies from manufacturer to manufacturer making it difficult to compare "apples to apples"; and the stakes are high when choosing wrong. Using a non-optimal product in an experiment can lead to flawed data, poor, or non-reproducible results. To help scientists make the best choice possible, Zageno has created a proprietary application algorithm that not only compares specifications, but also incorporates an independent, unbiased "Zageno Scientific Score," based on millions of scientific publications. For the scientist, this simplifies the comparison process, helping her choose the best performing product for her particular experiment, helping to identify and purchase critical products for the work more reliably and driving down time and cost to scientific result.

"With my background in lean six sigma, I'm very conscious of what constitutes value-add time versus non-value-add time, and in biotech research - time spent performing well-designed, reproducible experiments is the ultimate in value-add time," said Zageno Cofounder and Chief Executive Officer David Pumberger, Ph.D. "We have created this marketplace to streamline supply chains and make it as painless and efficient as possible so that all the researcher has to focus on is his or her end point."

About Thomas Scientific ( www.thomassci.com ; twitter:  @ThomasSci )
Thomas Scientific provides the latest in equipment and supplies to the science community. In accordance to the tradition of the original founders, Thomas Scientific itself offers individualized customer service, innovative scientific equipment, and a comprehensive catalog offering a wide selection of product listings at a great deal. We are a registered contractor for the U.S. Federal Government. Thomas Scientific is committed to offering quality laboratory products while catering to the unique needs of the individual customer. For over a century, our dedication to provide the best in science equipment with personal, efficient service sets Thomas apart from the competition. Whether you work in a lab setting or perform your testing in the field, Thomas Scientific has the products you need. We carry everything you need from all of your favorite and trusted suppliers, including Ansell, Avantor(TM) Performance Materials, Becton Dickinson, Buchi, Corning, GE Healthcare, Globe Scientific, Eppendorf, JG Finneran/Porvair, Kimble, Mettler Toledo, Microflex, MilliporeSigma, Thermo Scientific, Wheaton, and more.

About Zageno Inc. ( www.zageno.com ;  twitter:  @ZAGENOteam )
Founded in 2015, Zageno is eliminating bottlenecks to breakthrough science and research through curated connections linking scientists and their institutions' procurement offices with leading life science vendors. World-renowned academic and government research facilities, global pharmaceutical companies, and biotechs large and small are already users of our unique online biotech marketplace, currently comprising more than three million products. What do we do? 1) We help scientists choose the optimal laboratory kits and materials for each unique experiment setup. 2) We make purchasing transactions more efficient for both buyers and sellers. 3) For our vendor partners, we provide a valuable, expanded sales channel. Our growing Zageno team of 50 in Boston, USA, and Berlin, Germany, includes experts in science, e-commerce, systems integration, and customer support to enable smarter, faster processes - allowing more time and resources for value-added science and better research results.

 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/04a8c6dc-312c-4acb-826d-f8926c736be8

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7c42128a-faa4-40d4-aa2e-f662aa0a81dc

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6fb6f0ad-059d-4529-b2c8-a32e70601948

Caroline Grossman for Zageno
Mirepoix LLC
(781) 771-5579
Caroline@mirepoixllc.com

Diane Skala for Thomas Scientific
Thomas Scientific
(856) 832-3296
DianeS@thomassci.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum